Navigation Links
Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies

SOUTH EASTON, Mass., July 1 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists from the New York University ("NYU") School of Medicine and the Brooklyn Hospital Center presented results yesterday on advances they made in the areas of breast and colon cancer, stroke, and in vitro fertilization ("IVF"). The results were generated in studies using PBI's patented pressure cycling technology ("PCT") and patent-pending PCT-dependent ProteoSolve-LRS protein extraction kit. The presentations were made at the 2nd Annual Advances in Biomolecular Engineering: Protein Design Symposium, sponsored by the New York Academy of Sciences.

Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology) and principle investigator for the research studies, commented: "PCT is critical to our work. This novel, cutting-edge technology consistently gives us rapid and reliable extraction of proteins from our important samples. In addition -- and this is very exciting -- PCT has given us the additional extraordinary benefits of not only greater protein yield, but the extraction of proteins not previously identified in these types of samples. Consequently, we believe that the use of PCT, more than the use of any extraction technology available today, could lead to the discovery of new biomarkers for cancer and stroke, which in turn could lead to the development of new diagnostics and therapeutics to combat these diseases."

Dr. Pevsner continued: "Many IVF live births result in twins, triplets, and higher order births. Unfortunately, fetuses and mothers of multiple and high-order multiple pregnancies have increased morbidity and mortality. To combat this, more single embryo transfers are needed. To this end, we have been interested in identifying biomarkers for embryo viability and competence. Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth media only seen in competent embryos. These proteins may prove to be biomarkers that can enhance selection and result in more live births from single embryo transfers. These are very exciting results."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT to extract new proteins; the speed of sample preparation using PCT compared with other sample preparation methods; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins in cancer, stroke, and IVF samples; and the possibility that extraction of proteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced selection for single embryo transfers. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of PCT; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Pevsner and his colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer and stroke, and may not result in more live births from single embryo transfers; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President (508) 230-1828 (T)

of Finance & CFO

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
2. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
3. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
7. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
10. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
11. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The recently published 32nd Annual Report of ... that in 2014, someone called a poison center about every 11 seconds. America’s ... human exposure cases. , The American Association of Poison Control Centers (AAPCC) maintains ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast ... and prevention—is joining forces with the award-winning creator and writer of Downton Abbey ... 7, 2015 at the Union League of Philadelphia. , The benefit, titled ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about ... baby had high blood pressure due to loud noises," she said, "so I decided ... noise pollution as well as radio waves and microwaves." , The baby BABY MUFF ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
Breaking Medicine News(10 mins):